Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment

被引：0
|
作者：
Lichtenstein, Gary R. [1 ]
Loftus, Edward V., Jr. [2 ]
Bloom, Stuart [3 ]
Lawendy, Nervin [4 ]
Chan, Gary [4 ]
Friedman, Gary S. [4 ]
Zhang, Haiying [4 ]
Wang, Wenjin [4 ]
Thorpe, Andrew J. [4 ]
Nduaka, Chudy I. [4 ]
Su, Chinyu [4 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Pfizer Inc, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
571
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [21] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
    Hisashi Yamanaka
    Yoshiya Tanaka
    Tsutomu Takeuchi
    Naonobu Sugiyama
    Hirotoshi Yuasa
    Shigeyuki Toyoizumi
    Yosuke Morishima
    Tomohiro Hirose
    Samuel Zwillich
    Arthritis Research & Therapy, 18
  • [22] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
    Yamanaka, Hisashi
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Sugiyama, Naonobu
    Yuasa, Hirotoshi
    Toyoizumi, Shigeyuki
    Morishima, Yosuke
    Hirose, Tomohiro
    Zwillich, Samuel
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [23] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
    Abraham, Bincy P.
    Longman, Randy
    Katsanos, Konstantinos
    Lee, Scott D.
    Kobayashi, Taku
    Bettenworth, Dominik
    Korman, Louis
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, Annkatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Torres, Joana
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1063 - S1063
  • [24] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
  • [25] Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
    Feagan, Brian G.
    Matsuoka, Katsuyoshi
    Rogler, Gerhard
    Laharie, David
    Vermeire, Severine
    Danese, Silvio
    Loftus Jr, Edward V.
    Beales, Ian
    Schreiber, Stefan
    Kim, Hyo Jong
    Faes, Margaux
    de Haas, Angela
    Masior, Tomasz
    Rudolph, Christine
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 563 - 584
  • [26] PERSISTENCE OF TOFACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES UP TO 7 YEARS
    Pope, J.
    Keystone, E.
    Jamal, S.
    Wang, L.
    Fallon, L.
    Woolcott, J.
    Lazariciu, I.
    Haraoui, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 245 - 245
  • [27] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
    Pope, Janet E.
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Chapman, Douglass
    Haraoui, Boulos
    ACR OPEN RHEUMATOLOGY, 2019, 1 (02) : 73 - 82
  • [28] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [29] Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study
    Colombel, Jean-Frederic
    Reinisch, Walter
    Osterman, Mark T.
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Zhang, Haiying
    Lawendy, Nervin
    Friedman, Gary S.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S389 - S390
  • [30] Maintenance of Remission with Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis from an Open-Label, Long-Term Extension Study
    Jean-Frederic, Colombel
    Walter, Reinisch
    Mark, Osterman T.
    Andrew, Thorpe J.
    Chudy, Nduaka, I
    Zhang Haiying
    Nervin, Lawendy
    Gary, Friedman S.
    Su Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S4 - S4
12345